Skip to main content
Equibles

Dawn Schottlandt

Head of Investor Relations

Geron Corp (GERN)

Head of Investor Relations

Collegium Pharmaceutical, Inc (COLL)
Geron Corp (GERN)

Equibles does not estimate personal net worth.

Get an email with a short summary when Geron Corp publishes a filing, an earnings call transcript or a press release.

Get GERN alerts

About Dawn Schottlandt

Dawn Schottlandt is recorded as Head of Investor Relations at Geron Corp (GERN) and Head of Investor Relations at Collegium Pharmaceutical, Inc (COLL). Geron Corp reported in an 8-K filed October 14, 2025 that Dawn Schottlandt was appointed Senior Vice President, Investor Relations and Corporate Affairs, effective October 20, 2025. Dawn Schottlandt has spoken on 4 earnings calls across 1 company, most recently for Geron Corp on August 5, 2026. Geron Corp is classified in the Biotechnology industry within the Healthcare sector. Collegium Pharmaceutical, Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Geron Corp includes Elizabeth G. O'Farrell (Chairman and Board Member), Michelle J. Robertson (CFO), Shanthakumar Tyavanagimatt (CTO) and 7 others.

“Ms. Schottlandt is expected to join Geron on October 20, 2025.”
Geron Corp Form 8-K, filed October 14, 2025 · Read the filing

Dawn Schottlandt on recent calls

“Before we begin, please note that during the course of this presentation and question and answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations, and other projections, including those related to our 2026 financial guidance, our current Ritello…”
Head of Investor Relations, Q2 2026 Geron Earnings Conference Call ·
“Before we begin, please note that during the course of this presentation and question and answer session, we will be making forward-looking statements regarding future events, performance plans, expectations, and other projections, including those relating to our 2026 financial guidance, our current Ritello…”
Head of Investor Relations, Geron Corp Q1 FY2026 Earnings Call ·
“Before we begin, please note that during the course of this presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations, and other projections.”
Head of Investor Relations, Geron Corp Q3 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Geron Corp

Leadership on record at Collegium Pharmaceutical, Inc

Recent activity